Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 9,343

Document Document Title
WO/2024/056099A1
Provided is use of a compound of formula I, formula I', or formula I", and a tautomer, a stereoisomer, or a pharmaceutically acceptable salt thereof as an METTL3 inhibitor. The compound can be used for treating a condition and a disease ...  
WO/2024/057021A1
The present disclosure relates to a novel class of bifunctional molecules that are useful in a targeted or selective degradation of a protein.  
WO/2024/056090A1
Disclosed are a pyrrolopyrimidine derivative as an RSK inhibitor and use thereof. Specifically, disclosed are a compound represented by formula I, a pharmaceutical composition containing the compound of formula I, and use of the compound...  
WO/2024/059808A1
Compounds of general Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive ...  
WO/2024/059249A1
The present disclosure provides compounds of Formula I: (I), or an N- oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: A, Y, m, n, p, R1, R2, R3, R3a, R4, R5, R6, R7, and Z are as described he...  
WO/2024/059200A1
Compounds having activity as inhibitors of NEK7 are provided. The compounds have Structure (I): (I) or a stereoisomer, tautomer, or salt thereof, wherein A, W, X, Y, Z, R1, and R2 are as defined herein. Methods associated with preparatio...  
WO/2024/059845A1
A method of inhibiting propagation of protein misfolding associated with a neurological disease, is carried out by contacting an environment populated with a propagating amyloid conformation of a protein (prion) associated with a neurolo...  
WO/2024/059558A1
The present disclosure relates generally to compounds of Formulae (l-A), (l-B1), (l-C) and ((l-D) and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, method...  
WO/2024/026483A3
The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.  
WO/2024/055112A1
The disclosure relates to bifunctional KRAS-G12D-modulating compounds having the structure W-L-T, where W is a targeting group that binds specifically to KRAS-G12D protein, T is an E3-ligase binding group, and L is absent or is a bivalen...  
WO/2024/051852A1
The present invention relates to a pyrimidine-containing polycyclic biological inhibitor, a preparation method therefor, and use thereof. In particular, the present invention relates to a pyrimidine-containing polycyclic compound or a st...  
WO/2024/052513A1
The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions contain...  
WO/2024/051721A1
The present disclosure provides certain tetracyclic derivatives that inhibit certain K-Ras proteins and are therefore useful for the treatment of cancers mediated by such proteins. Also provided are pharmaceutical compositions containing...  
WO/2024/051784A1
Provided are a nitrogen-containing heterocyclic compound, a pharmaceutical composition thereof, and use thereof. The structure of the nitrogen-containing heterocyclic compound is represented by formula I. The nitrogen-containing heterocy...  
WO/2024/052512A1
The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions contain...  
WO/2024/054603A1
The invention provides heterobifunctional compounds which may bind to both an androgen receptor and BRD4 (bromodomain-containing protein 4). Also provided are pharmaceutical compositions comprising the same and their use in treating dise...  
WO/2024/053650A1
The present invention addresses the problem of providing a compound having inhibitory activity against DGK α and/or ζ. As a result of diligent study, the inventors of the present invention found, as a substance that can solve the abo...  
WO/2024/050640A1
The disclosure relates to KRASG12D inhibitor compounds having the structure of Formula (A) or Formula (B), pharmaceutical compositions thereof, and methods of use thereof for inhibiting, treating, and/or preventing KRASG12D mutation-asso...  
WO/2024/054926A1
The present disclosure relates to KRAS inhibitors. Methods of treating cancers using the compounds are also provided.  
WO/2024/050708A1
The present invention relates to the field of organic display, and in particular to a blue light emitting guest material and a preparation method therefor, and an organic light emitting device. The blue light emitting guest material is a...  
WO/2024/046471A1
The present application provides a class of novel compounds having a USP1 inhibitory activity as shown in formula (II'), pharmaceutical compositions comprising the compounds, useful intermediates for preparing the compounds, and a method...  
WO/2024/046420A1
The present disclosure relates to a fused bicyclic compound, and a preparation method therefor and the use thereof in medicine. Specifically, the present disclosure relates to a fused bicyclic compound as shown in general formula (I), a ...  
WO/2024/050370A1
The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usef...  
WO/2024/046406A1
Provided herein are certain alkylidenyl carbamate compounds that inhibit certain K-Ras proteins and are therefore useful for the treatment of cancers mediated by such proteins. Also provided are pharmaceutical compositions containing suc...  
WO/2024/046370A1
The present invention relates to compounds of formula (I) and formula (II), or pharmaceutically acceptable salts, prodrugs, tautomers, or stereoisomers and solvates thereof. Said compounds can be used for the treatment of cancers and inf...  
WO/2024/048519A1
Provided are: a pyrazolopyrimidine compound having an inhibitory activity on NLRP3 inflammasomes or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing the same; a pharmaceutical use thereof, etc. A compou...  
WO/2024/045066A1
Provided are certain alkylidenyl carbamate compounds that inhibit certain K-Ras proteins and are therefore useful for the treatment of cancers mediated by such proteins. Also provided are pharmaceutical compositions containing such compo...  
WO/2024/042361A1
Described herein are compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, disease...  
WO/2024/041643A1
The present disclosure relates to a fused tricyclic compound, a preparation method therefor, and medical use thereof. Specifically, the present disclosure relates to a fused tricyclic compound represented by general formula (I), a prepar...  
WO/2024/042316A1
This invention relates to novel compounds and pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as inhibitors of discoidin domain receptor 1 (DDR1) and discoidin doma...  
WO/2024/041589A1
Disclosed are a nitrogen-containing heterocyclic compound, a preparation method therefor, an intermediate thereof, and use thereof. Specifically, the present invention provides a nitrogen-containing heterocyclic compound as represented b...  
WO/2024/044344A1
The invention provides pyridinylsulfonamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condi...  
WO/2024/041183A1
The present application relates to an organic compound, an organic electroluminescent device, and an electronic apparatus. The organic compound of the present application has a structure represented by formula (1). By applying the organi...  
WO/2023/073641A9
This invention provides for compounds of the formula: (I) wherein the variables are defined herein, or salt thereof, compositions comprising these compounds, and methods for the treatment, control and/or prevention of a parasitic infesta...  
WO/2024/042494A1
The inventive compounds are small molecule therapeutics that are potent inhibitors of USP7 activity. The invention also provides pharmaceutical compositions comprising the compounds, and methods for using the compounds for treating or pr...  
WO/2024/041621A1
The invention provides K-Ras mutant protein inhibitors of formula (Ⅰ), a composition containing the same and the use thereof.  
WO/2024/041573A1
This application discloses compounds of formula (I), which can be inhibitors of KRAS G12D or other KRAS mutants, and their uses.  
WO/2024/041606A1
The present invention provides a compound represented by formula (I) for use as a KRAS inhibitor, a pharmaceutical composition comprising the compound, a method for preparing the compound, and use of the compound in treating a cancer.  
WO/2024/040190A1
Provided are compounds of Formula (I). Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formu...  
WO/2024/038356A1
The present disclosure includes synthetic methods for preparing certain substituted 1-aryl-1'-heteroaryl and 1,1'-biheteroaryl compounds, which can be used to treat, ameliorate, and/or prevent hepatitis B virus (HBV) infections in a pati...  
WO/2024/040109A2
The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.  
WO/2024/037459A1
Provided are a series of amide-containing heterocyclic derivatives and the use thereof, and specifically provided are compounds represented by formula (III) and pharmaceutically acceptable salts thereof.  
WO/2024/032598A1
The present application relates to a TGF-β inhibitor compound and the use thereof. Specifically, disclosed in the present application is a compound as represented by formula (I), or an isotope-labeled compound thereof, or an optical iso...  
WO/2024/036097A1
Provided herein are heteroaromatic macrocyclic ether compounds and isotopologues thereof, or a stereoisomer, or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof, and methods of treating, preventing or man...  
WO/2024/036270A1
The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.  
WO/2024/033277A1
The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, R1, R2, R4, and R5 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of usin...  
WO/2024/032529A1
Provided are a protein degradation agent and a preparation method therefor and a pharmaceutical use thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method therefor, a ...  
WO/2024/032589A1
Provided are a TGF-β inhibitor compound and use thereof. In particular, provided is a compound represented by formula (I) or formula (II) or an isotopically labeled compound, an optical isomer, a geometric isomer, a tautomer, an isomer ...  
WO/2024/032673A1
A compound represented by formula I, stereoisomers or pharmaceutically acceptable salts thereof, or a pharmaceutical composition containing same, and the use thereof as a PDE4B inhibitor in the preparation of a drug for treatment of rela...  
WO/2024/035627A1
The present disclosure provides heterocyclic amide and urea compounds and compositions thereof useful for inhibiting JAK2.  

Matches 1 - 50 out of 9,343